Prosecution Insights
Last updated: May 29, 2026

Examiner: DHARITHREESAN, NIDHI

Tech Center 1600 • Art Units: 1672 1686

This examiner grants 40% of resolved cases

Performance Statistics

40.4%
Allow Rate
-19.6% vs TC avg
82
Total Applications
+37.6%
Interview Lift
1734
Avg Prosecution Days
Based on 47 resolved cases, 2023–2026

Rejection Statute Breakdown

17.3%
§101 Eligibility
17.3%
§102 Novelty
40.4%
§103 Obviousness
4.4%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17748455 UMI COLLAPSING Final Rejection Illumina, Inc.
16776405 PATHOGEN DETECTION USING NEXT GENERATION SEQUENCING Final Rejection The Regents of the University of California
17259128 METHODS AND SYSTEMS FOR DETECTING AND QUANTIFYING NUCLEIC ACIDS Non-Final OA GEN-PROBE INCORPORATED
16485649 METHOD AND SYSTEMS FOR THE EFFICIENT COMPRESSION OF GENOMIC SEQUENCE READS Non-Final OA KONINKLIJKE PHILIPS N.V.
17490615 ANTI-COUNTERFEIT TAGS USING HIGH-COMPLEXITY POLYNUCLEOTIDES Non-Final OA MICROSOFT TECHNOLOGY LICENSING, LLC
16939421 SAFEGUARDING MEASURES FOR A CLOSED-LOOP INSULIN INFUSION SYSTEM Non-Final OA MEDTRONIC MINIMED, INC.
17948256 CULTIVATION SUPPORT SYSTEM, CULTIVATION SUPPORT METHOD, AND RECORDING MEDIUM Final Rejection Yokogawa Electric Corporation
17263602 BIOPOLYMER ANALYSIS METHOD AND BIOPOLYMER ANALYSIS DEVICE Final Rejection Hitachi High-Tech Corporation
17136351 IN-SILICO DESIGN OF ELECTROPORATION EXPERIMENTS FOR TOPICAL AND TRANSDERMAL DRUG DELIVERY APPLICATIONS Non-Final OA Tata Consultancy Services Limited
17491276 TECHNIQUES FOR ACCELERATING SMITH-WATERMAN SEQUENCE ALIGNMENTS Final Rejection NVIDIA CORPORATION
17047197 SYSTEMS AND METHODS FOR QUANTITATIVELY PREDICTING RESPONSE TO IMMUNE-BASED THERAPY IN CANCER PATIENTS Final Rejection H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
17285459 MULTIVARIATE APPROACH FOR CELL SELECTION Final Rejection Sartorius Stedim Data Analytics AB
17849161 METHODS FOR DIAGNOSING AND EVALUATING NON-ALCOHOLIC STEATOHEPATITIS Non-Final OA Genfit
16631644 SCANSOFT: A METHOD FOR THE DETECTION OF GENOMIC DELETIONS AND DUPLICATIONS IN MASSIVE PARALLEL SEQUENCING DATA Non-Final OA Siemens Healthcare GmbH
16153071 METHOD FOR OPTIMIZING FLUORESCENCE-BASED DETECTION Final Rejection Nomic Bio Inc.
17642030 SYSTEMS AND METHODS FOR ARTIFICAL INTELLIGENCE BASED CELL ANALYSIS Non-Final OA Aikili Biosystems, Inc.
17058165 METHOD AND SYSTEM FOR USE IN DIRECT SEQUENCING OF RNA Non-Final OA New York Institute of Technology

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month